Neuroleptic medication is clearly effective in alleviating psychotic symptoms and reducing relapse rates in schizophrenia. However, some patients do not respond to such treatment and others respond equally well on placebo. Thus, neuroleptic treatment may be unwarranted for some types of schizophrenia. Since neuroleptic treatment is associated with deleterious and sometimes irreversible side effects, the delineation of subtypes not requiring medication has direct implications for clinical care. Our review of the literature also suggests that attention to treatment responsiveness may help to resolve the problem of genetic heterogeneity in schizophrenia. Hypotheses are derived from two alternative models of heterogeneity to predict clinical, familial and neuropsychological characteristics among treatment response subtypes. Three subtypes will be examined. Chronically psychotic, neuroleptic independent patients will be defined on the basis of a medical record history of unremitting psychotic symptoms and adequate neuroleptic bioavailability on their usual clinical dose. Neuroleptic dependent patients will be defined on the basis of a medical record history of remitting psychotic symptoms and the observation of clinical relapse during a six month trial of a 80% dose reduction. Episodically psychotic patients will have had a medical record history of remitting psychotic symptoms but will not have relapsed during dose reduction despite evidence of low neuroleptic bioavailability as measured by serum neuroleptic and serum prolactin levels. Before the dose reduction phase, all patients will be assessed with the Diagnostic Interview Schedule to verify a DSM-III diagnosis of schizophrenia, the Luria-Nebraska Neuropsychological Battery to assess neuropsychological functioning and psychosocial measures to assess the severity of the disorder and the presence of moderating factors. We expect the 60 subjects in each drug response group to have an average of 2.5 biological relatives available for interview. These 450 relatives will be assessed with the Diagnostic Interview Schedule and the Structured Interview for DSM-III Personality Disorders to determine psychiatric diagnoses of schizophrenia and schizophrenia related personality disorders. The assessment and diagnosis of relatives will be blind to the assessment and diagnosis of probands and vice-versa. All proband and relative assessments will be blind to drug response status. Data analyses will test predictions from Multifactorial Polygenic and Discrete Subtype models of genetic heterogeneity to develop rules for predicting treatment response and familial risk.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH041874-03
Application #
3380772
Study Section
(PCBA)
Project Start
1987-02-01
Project End
1991-01-31
Budget Start
1989-03-01
Budget End
1991-01-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Massachusetts Mental Health Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02210
Takahashi, Sakae; Cui, Yu-hu; Han, Yong-hua et al. (2008) Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. Schizophr Res 104:153-64
Takahashi, Sakae; Faraone, Stephen V; Lasky-Su, Jessica et al. (2005) Genome-wide scan of homogeneous subtypes of NIMH genetics initiative schizophrenia families. Psychiatry Res 133:111-22
Faraone, Stephen V; Su, Jessica; Taylor, Levi et al. (2004) A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Hum Hered 57:59-68
Takahashi, Sakae; Cui, Yu-Hu; Kojima, Takuya et al. (2003) Family-based association study of markers on chromosome 22 in schizophrenia using African-American, European-American, and Chinese families. Am J Med Genet B Neuropsychiatr Genet 120B:11-7
Lewis, Cathryn M; Levinson, Douglas F; Wise, Lesley H et al. (2003) Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73:34-48
Wilcox, Marsha A; Faraone, Stephen V; Su, Jessica et al. (2002) Genome scan of three quantitative traits in schizophrenia pedigrees. Biol Psychiatry 52:847-54
Faraone, S V; Green, A I; Seidman, L J et al. (2001) ""Schizotaxia"": clinical implications and new directions for research. Schizophr Bull 27:1-18
Faraone, S V; Seidman, L J; Kremen, W S et al. (2000) Neuropsychologic functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading. Biol Psychiatry 48:120-6
Faraone, S V; Meyer, J; Matise, T et al. (1999) Suggestive linkage of chromosome 10p to schizophrenia is not due to transmission ratio distortion. Am J Med Genet 88:607-8
Faraone, S V; Seidman, L J; Kremen, W S et al. (1999) Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a 4-year follow-up study. J Abnorm Psychol 108:176-81

Showing the most recent 10 out of 27 publications